within Pharmacolibrary.Drugs.ATC.J;

model J01DI02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00016166666666666665,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.020300000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.011699999999999999,
    k12             = 12.6,
    k21             = 12.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DI02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ceftaroline fosamil is a broad-spectrum, fifth-generation cephalosporin antibiotic approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults and children. It is active against a range of Gram-positive and Gram-negative organisms, including methicillin-resistant Staphylococcus aureus (MRSA). The drug is administered as a prodrug (fosamil form), which is rapidly converted to the active ceftaroline in vivo.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Grau, S, et al., &amp; Luque, S (2014). [Pharmacokinetics and pharmacodynamics of ceftaroline]. <i>Enfermedades infecciosas y microbiologia clinica</i> 32 Suppl 2 15–20. DOI:<a href=&quot;https://doi.org/10.1016/S0213-005X(14)70153-3&quot;>10.1016/S0213-005X(14)70153-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24702974/&quot;>https://pubmed.ncbi.nlm.nih.gov/24702974</a></p></li><li><p>Edlinger-Stanger, M, et al., &amp; Hutschala, D (2021). Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an . <i>Antimicrobial agents and chemotherapy</i> 65(10) e0067921–None. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00679-21&quot;>10.1128/AAC.00679-21</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34280013/&quot;>https://pubmed.ncbi.nlm.nih.gov/34280013</a></p></li><li><p>Esposito, S, et al., &amp; Kantecki, M (2021). Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia. <i>Paediatric drugs</i> 23(6) 549–563. DOI:<a href=&quot;https://doi.org/10.1007/s40272-021-00468-w&quot;>10.1007/s40272-021-00468-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34462863/&quot;>https://pubmed.ncbi.nlm.nih.gov/34462863</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DI02;
